Search

Highlights from the SWG

The following activities, which were organized by EMN, also constitute contributions to and participation in the work of the EHA SWG on Multiple Myeloma.

Read more

Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

Read more

Highlights from the SWG

Participation in EHA and ASH congresses. Planning of new common trials. Conduct of annual EMSCO meeting in Nice in October 2023.

Read more

Publications

Original scientific publications
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Fandrei D, Huynh T, Sébert M, Aguinaga L, Bisio V, Kim R, Clappier E, Espéli M, Balabanian K, Moins-Teisserenc H, Toubert A, Dulphy N, Fenaux…

Read more

SWG Educational Activities

EHA-SWG meetingsAn EMSCO meeting was held in October 2023 (Nice, France).

Read more

Highlights of the SWG

SWG business meetingWe held a key strategic SWG business meeting on November 29, 2023, at the EHA offices in The Hague. During the meeting, we discussed the future plans and priorities of our SWG.

Read more

Highlights from the SWG

Project groupsPan-European Transfusion Research infrAstructure (PETRA) projectThe European Blood Alliance has provided funding for a health science data project entitled: ‘Towards a Pan-European Transfusion Research infrAstructure (PETRA).

Read more

Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report

Healthy subjects frequently report minor bleedings that are frequently ‘background noise’ of normality rather than a true disorder. Nevertheless, unexpected or unusual bleeding may be alarming.

Read more

Highlights of the EHA-EMA Joint Symposium on RWE

The fourth EHA-EMA Joint Symposium at EHA2024 brought together investigators, regulators and patients to discuss the use of real world evidence (RWE) in the evaluation of new drugs.

Read more